A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections
Information source: Kaohsiung Medical University Chung-Ho Memorial Hospital
Information obtained from ClinicalTrials.gov on October 04, 2010
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Intra-abdominal Infection
Intervention: moxifloxacin (Drug); ampicillin/sulbactam (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Kaohsiung Medical University Chung-Ho Memorial Hospital Overall contact:
Chao-wen Chen, MD/MPH, Phone: 886-7-3121101, Ext: 7553, Email: ytljwc@gmail.com
Summary
On the basis of monotherapy for intra-abdominal infection, the investigators are conducting
this study to identify the difference of drug efficacy between ampicillin/sulbactam and
moxifloxacin.
Clinical Details
Official title: A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections
Study design: Allocation: Randomized, Control: Active Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: clinical response at test-of-cure visit
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients diagnosed of complicated intra-abdominal infection need surgical treatment
Exclusion Criteria:
- patients diagnosed of intra-abdominal infection receive non-operative management
- patients with known allergic history of fluoroquinolone
- Severe, life threatening disease with a life expectancy of < 48 h or APS and APACHE
scores of > 35
Locations and Contacts
Chao-wen Chen, MD/MPH, Phone: 886-7-3121101, Ext: 7553, Email: ytljwc@gmail.com
Kaohsiung Medical University Hospital, Department of Emergency Medicine/Surgery, Kaohsiung 804, Taiwan; Recruiting
Jaw-yuan Wang, MD/PhD
Additional Information
Starting date: March 2009
Last updated: August 4, 2009
|
